Multispecific BCMA Binders for T-Cell Co-Stimulation in B-Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current redirected targeted T-cell lysis (RTCC) approaches targeting BCMA are limited in effectively engaging multiple pathways for enhanced T-cell mediated lysis and proliferation against cancerous B cells, particularly in B cell malignancies.
Innovation Solution
Development of multispecific binding molecules (MBMs) that simultaneously engage BCMA, CD3 or a component of the TCR complex, and either CD2 or a human tumor-associated antigen (TAA), incorporating at least three antigen-binding modules (ABMs) to stimulate both primary signaling and co-stimulatory pathways, potentially overcoming anergy and improving therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bispecific engagers targeting only BCMA and TCR complex component are used, then T-cell mediated lysis of tumor cells is achieved, but T-cell proliferation is not induced and anergy cannot be overcome
Solution Approach 1:
The patent combines multiple functional binding modules into a single multispecific binding molecule. The molecule includes a first binding module for BCMA, a second binding module for TCR complex component (CD3), a third binding module for CD2 (co-stimulatory pathway), and optionally a fourth binding module for additional TAA. This merging approach integrates tumor targeting, T-cell engagement, and co-stimulation induction into one molecule, resolving the contradiction by achieving reliable T-cell proliferation without requiring multiple separate agents.
Solution Approach 2:
The multisspecific binding molecule is designed to perform multiple functions simultaneously: (1) target tumor cells via BCMA and/or TAA binding, (2) engage T-cells via TCR complex component binding, (3) induce co-stimulatory signaling via CD2 binding, and (4) promote T-cell proliferation. This multi-functionality allows a single molecule to address all limitations of conventional bispecific engagers, achieving both tumor lysis and T-cell proliferation induction.
2Productivity
If conventional RTCC approaches are used, then treatment simplicity is maintained, but the number of cancerous B cells that can be targeted is limited
Solution Approach 1:
The patent merges multiple targeting capabilities into one molecule by including optional fourth binding modules for additional TAAs. This allows the same multisspecific binding molecule to target different cancerous B cells expressing different TAAs (BCMA, CD19, CD20, etc.), thereby increasing the number of cancerous B cells that can be targeted while maintaining treatment simplicity through single-molecule administration.
3Reliability
If multisspecific binding molecules with multiple binding modules are developed, then both primary signaling and co-stimulatory pathway are activated, but the molecular structure becomes more complex
Solution Approach 1:
The patent segments the multisspecific binding molecule into distinct functional binding modules: first binding module (BCMA), second binding module (TCR complex component), third binding module (CD2), and optional fourth binding module (additional TAA). Each module can be independently designed and optimized, allowing systematic construction of the complex molecule while maintaining clarity in structure-function relationships. This segmentation approach makes the complex molecule more manageable and easier to engineer.
Data Source
AI summary
The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates. The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.